Pfizer Inc. (NYSE:PFE) Shares Purchased by Liberty One Investment Management LLC

Liberty One Investment Management LLC raised its position in Pfizer Inc. (NYSE:PFE) by 4.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 993,474 shares of the biopharmaceutical company’s stock after acquiring an additional 39,532 shares during the quarter. Pfizer accounts for about 2.9% of Liberty One Investment Management LLC’s investment portfolio, making the stock its 14th largest holding. Liberty One Investment Management LLC’s holdings in Pfizer were worth $26,357,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in PFE. McElhenny Sheffield Capital Management LLC boosted its stake in shares of Pfizer by 6.7% in the fourth quarter. McElhenny Sheffield Capital Management LLC now owns 17,631 shares of the biopharmaceutical company’s stock valued at $468,000 after purchasing an additional 1,114 shares during the period. Clarius Group LLC boosted its position in Pfizer by 16.0% in the 4th quarter. Clarius Group LLC now owns 30,747 shares of the biopharmaceutical company’s stock valued at $816,000 after buying an additional 4,250 shares during the last quarter. HF Advisory Group LLC boosted its position in Pfizer by 3.3% in the 4th quarter. HF Advisory Group LLC now owns 91,402 shares of the biopharmaceutical company’s stock valued at $2,425,000 after buying an additional 2,916 shares during the last quarter. Aaron Wealth Advisors LLC grew its stake in shares of Pfizer by 18.5% during the fourth quarter. Aaron Wealth Advisors LLC now owns 19,645 shares of the biopharmaceutical company’s stock valued at $521,000 after acquiring an additional 3,069 shares in the last quarter. Finally, Monarch Capital Management Inc. lifted its stake in shares of Pfizer by 7.6% in the fourth quarter. Monarch Capital Management Inc. now owns 115,382 shares of the biopharmaceutical company’s stock worth $3,061,000 after acquiring an additional 8,152 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on PFE shares. Guggenheim dropped their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Pfizer Stock Down 0.7 %

Shares of Pfizer stock opened at $26.30 on Friday. The stock has a market capitalization of $149.06 billion, a price-to-earnings ratio of 35.55, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business’s 50 day simple moving average is $26.08 and its 200-day simple moving average is $27.99.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the business posted ($0.17) earnings per share. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.54%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is presently 232.43%.

Insider Activity

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.